CAR-T Pipeline Report Provides detailed information of the CAR-T Pipeline products from the initial phase of product development until its commercialization

CAR-T Pipeline Insights, Assessment, Drugs, Companies Report

DelveInsight&rsquo;s, &ldquo;CAR-T Pipeline Insight 2025,&rdquo; report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in CAR-T pipeline landscape. It covers the CAR-T Pipeline Drugs profiles, including clinical and nonclinical stage products. It also covers the CAR-T Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
<ul>
<li>Global coverage</li>
</ul>
<h2><a title="CAR-T Pipeline" href="https://www.delveinsight.com/sample-request/car-t-pipeline-insight"><img src="https://delveinsight-images.s3.amazonaws.com/products/ck-editor/CAR-T%20-%20Pipeline%20Insight.png" alt="CAR-T Pipeline" width="800" height="420" /></a></h2>
<h2>CAR-T Pipeline: Understanding</h2>
CAR-T cell therapy represents a revolutionary approach in cancer treatment, harnessing the power of the immune system to combat cancer. This cutting-edge therapy involves a meticulous process where a patient's own T cells, a vital component of the immune system responsible for identifying and eliminating foreign invaders, are genetically engineered to specifically target and destroy cancer cells. The process begins by extracting T cells from the patient's blood through a process called <a href="https://www.delveinsight.com/report-store/leukapheresis-market">leukapheresis</a>. Once isolated, these T cells undergo genetic modification in the laboratory. Specifically, scientists introduce a gene encoding a chimeric antigen receptor (CAR) into the T cells. This CAR is designed to recognize and bind to a specific protein expressed on the surface of cancer cells. This customization ensures that the engineered T cells can specifically target and attack cancerous cells while sparing healthy cells.
After the genetic modification, the CAR T cells undergo extensive expansion in the laboratory, multiplying into large numbers. This amplification phase is crucial to generating a sufficient number of modified T cells for effective treatment. Once the CAR T cells reach the desired quantity, they are infused back into the patient's bloodstream through intravenous infusion. Upon infusion, these engineered T cells circulate throughout the body, seeking out cancer cells that express the target protein recognized by the CAR.
Upon encountering cancer cells, the CAR T cells bind to the specific protein expressed on their surface, triggering a cascade of immune responses that ultimately lead to the destruction of the cancerous cells. This includes the activation of cytotoxic pathways within the CAR T cells, resulting in the targeted killing of cancer cells. CAR-T cell therapy has demonstrated remarkable success in the treatment of certain blood cancers, such as leukemia and lymphoma, particularly in patients who have not responded to conventional treatments like chemotherapy or stem cell transplantation.
Moreover, ongoing research is exploring the potential of <a href="https://www.delveinsight.com/report-store/cart-cell-therapy-competitive-landscape">CAR-T cell therapy</a> in treating other types of cancers, including solid tumors. While CAR-T cell therapy offers tremendous promise, it also comes with unique challenges and potential side effects, including <a href="https://www.delveinsight.com/report-store/cytokine-release-syndrome-market">cytokine release syndrome</a> (CRS) and neurotoxicity, which require careful management and monitoring by healthcare professionals. CAR-T cell therapy represents a groundbreaking advancement in cancer treatment, offering a personalized and targeted approach to fighting cancer by harnessing the body's own immune system. With continued research and refinement, CAR-T cell therapy holds the potential to revolutionize the treatment landscape for various types of cancer, offering hope to patients who previously had limited treatment options.
"CAR-T Pipeline Insight 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the CAR-T Pipeline landscape is provided which includes the disease overview and CAR-T treatment guidelines. The assessment part of the report embraces, in depth CAR-T commercial assessment and clinical assessment of the pipeline products under development. In the CAR-T Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, CAR-T collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
<h2>CAR-T Pipeline Report Highlights</h2>
The CAR-T Companies and academics are working to assess challenges and seek opportunities that could influence CAR-T R&amp;D. The CAR-T Therapies under development are focused on novel approaches to treat/improve CAR-T.&nbsp;
&nbsp;
<h3>CAR-T Drugs Chapters</h3>
This segment of the CAR-T Pipeline Report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand CAR-T Clinical Trials details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
&nbsp;
<h3>CAR-T Emerging Drugs Profile</h3>
<ul>
<li>Descartes-08: Cartesian Therapeutics</li>
</ul>
Descartes-08 is an autologous <a href="https://www.delveinsight.com/report-store/b-cell-maturation-antigen-targeted-therapies-market">anti-B cell maturation antigen</a> (BCMA) mRNA CAR-T. Compared to conventional DNA-based CAR T-cell therapies, mRNA CAR-T is designed not to require preconditioning chemotherapy, has been observed to have predictable and controllable pharmacokinetics, and is designed to avoid the risk of genomic integration. Descartes-08 has been granted Orphan Drug Designation by the US FDA for the treatment of MG, a chronic autoimmune disorder that causes disabling muscle weakness and fatigue. Currently, the drug is in Phase II stage of clinical trial for the treatment of autoimmune disorders.
&nbsp;
<ul>
<li>KYV-101: Kyverna Therapeutics</li>
</ul>
KYV-101 is an autologous, fully human <a href="https://www.delveinsight.com/report-store/cd19-market-forecast">CD19</a> CAR T-cell product candidate for use in B cell-driven autoimmune diseases. The CAR in KYV-101 was designed by the National Institutes of Health (NIH) to improve tolerability and tested in a 20-patient Phase 1 trial in oncology. Results were published by the NIH in Nature Medicine3. KYV-101 is currently being evaluated in sponsored, open-label, Phase 1/2 trials of KYV-101 in patients with lupus nephritis, an autoimmune disease in which more than half of patients do not achieve a complete response to current therapies and are at risk of developing kidney failure. Additionally, FDA's IND clearance has been obtained for Phase 2 trials of KYV-101 for <a href="https://www.delveinsight.com/report-store/multiple-sclerosis-market">multiple sclerosis</a> and <a href="https://www.delveinsight.com/report-store/myasthenia-gravis-market">myasthenia gravis</a>, and a Phase I/II trial for <a href="https://www.delveinsight.com/report-store/systemic-sclerosis-market">systemic sclerosis</a>.
&nbsp;
<ul>
<li>TX200: Sangamo Therapeutics</li>
</ul>
TX200 is composed of the patient&rsquo;s own (autologous) <a href="https://www.delveinsight.com/report-store/regulatory-t-cells-tregs-market-forecast">regulatory T cells</a> (Tregs) engineered to express a <a href="https://www.delveinsight.com/report-store/chimeric-antigen-receptor-car-t-cell-therapy-market">chimeric antigen receptor</a> (CAR) designed to recognize the HLA-A2 protein present on a transplanted kidney and bind to it. TX200 is in development for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation from a living donor. It is in Phase I/II stage of its clinical trial.
&nbsp;
<ul>
<li>ALLO-605: Allogene Therapeutics</li>
</ul>
ALLO-605, a next-generation AlloCAR T&trade; known as a TurboCAR&trade;, is an investigational product that targets the B-cell maturation antigen (BCMA) for the treatment of patients with relapsed/refractory multiple myeloma and other BCMA-positive malignancies. This study uses ALLO-647, Allogene's proprietary <a href="https://www.delveinsight.com/report-store/monoclonal-antibody-market">monoclonal antibody</a> (mAb), as a part of its differentiated lymphodepletion regimen. ALLO-605 incorporates Allogene&rsquo;s proprietary TurboCAR technology, which allows for cytokine activation signaling to be engineered selectively into CAR T cells. In June 2021, ALLO-605 was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the potential treatment of relapsed/refractory multiple myeloma. The Phase 1 study evaluating ALLO-605 is underway. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of Multiple Myeloma.
&nbsp;
<ul>
<li>ATA3219: Atara Biotherapeutics&nbsp;</li>
</ul>
ATA3219 combines the natural biology of unedited T cells with the benefits of an allogeneic therapy. It consists of allogeneic Epstein-Barr virus (EBV)-sensitized T cells that express a CD19 CAR construct for the treatment of CD19+ relapsed or refractory B-cell malignancies, including B-cell non-Hodgkin&rsquo;s lymphoma and B-cell mediated autoimmune diseases including systemic lupus erythematosus (SLE) with kidney involvement (lupus nephritis [LN]). ATA3219 has been optimized to offer a potential best-in-class profile, featuring off-the-shelf availability. Currently, the drug is in Phase I stage of its clinical trial.
&nbsp;
<ul>
<li>CB-010: Caribou Biosciences</li>
</ul>
CB-010 is an allogeneic <a href="https://www.delveinsight.com/report-store/anti-cd19-antibody-pipeline-insight">anti-CD19</a> CAR-T cell therapy for the treatment of patients with relapsed or refractory <a href="https://www.delveinsight.com/report-store/b-cell-non-hodgkin-lymphoma-market">B cell non-Hodgkin lymphoma</a> (r/r B-NHL). CB-010 is the first allogeneic CAR-T cell therapy, to our knowledge, in a clinical trial with a PD-1 knockout, a genome-editing strategy designed to improve antitumor activity by limiting premature CAR-T cell exhaustion. CB-010 is being evaluated in the ongoing, open-label, multicenter ANTLER&nbsp; Phase I clinical trial in adults with r/r B-NHL.
Further product details are provided in the report&hellip;&hellip;..
<h3>CAR-T Pipeline Therapeutics Assessment</h3>
This segment of the CAR-T pipeline report provides insights about the different CAR-T drugs segregated based on following parameters that define the scope of the report, such as:
&nbsp;
Major CAR-T Companies
There are approx. 180+ key companies which are developing the therapies for CAR-T. The CAR-T Companies which have their CAR-T drug candidates in the most advanced stage, i.e. Phase II include, Cartesian Therapeutics.
<h3>&nbsp;</h3>
Phases
DelveInsight&rsquo;s CAR-T Pipeline Report covers around 200+ products under different phases of clinical development like
<ul>
<li>Late-stage products (Phase II and Phase II/III)</li>
<li>Mid-stage products (Phase II and Phase II/III)</li>
<li>Early-stage products (Phase I/II and Phase I) along with the details of</li>
<li>Pre-clinical and Discovery stage candidates</li>
<li>Discontinued &amp; Inactive candidates</li>
</ul>
&nbsp;
Route of Administration
CAR-T Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.&nbsp;CAR-T Products have been categorized under various ROAs such as
<ul>
<li>Oral</li>
<li>Intravenous</li>
<li>Subcutaneous</li>
<li>Parenteral&nbsp;</li>
<li>Topical</li>
</ul>
&nbsp;
Molecule Type
CAR-T Products have been categorized under various Molecule types such as
<ul>
<li>Recombinant fusion proteins</li>
<li>Small molecule</li>
<li>Monoclonal antibody</li>
<li>Peptide</li>
<li>Polymer&nbsp;</li>
<li>Gene therapy</li>
</ul>
&nbsp;
Product Type
CAR-T Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
<h3>CAR-T Pipeline Development Activities</h3>
The CAR-T Pipeline Report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Key CAR-T Companies &amp; therapeutic drugs&nbsp; involved in developing key drugs.
<h3>&nbsp;</h3>
Pipeline Development Activities
The CAR-T Pipeline Report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging CAR-T drugs.
<h3>&nbsp;</h3>
<h3>CAR-T Pipeline Report Insights</h3>
<ul>
<li>CAR-T Pipeline Drugs Analysis</li>
<li>CAR-T Pipeline Therapeutic Assessment</li>
<li>CAR-T Pipeline Unmet Needs</li>
<li>Impact of CAR-T Pipeline Drugs</li>
</ul>
<h3>&nbsp;</h3>
<h3>CAR-T Pipeline Report Assessment</h3>
<ul>
<li>CAR-T Pipeline Pipeline Drugs Profiles</li>
<li>CAR-T Pipeline Therapeutic Assessment</li>
<li>CAR-T Pipeline Pipeline Assessment</li>
<li>Inactive CAR-T Pipeline Drugs Assessment</li>
<li>CAR-T Pipeline Unmet Needs</li>
</ul>
&nbsp;
Key Questions
Current CAR-T Treatment Scenario and Emerging Therapies:
<ul>
<li>How many companies are developing CAR-T Drugs?</li>
<li>How many CAR-T Drugs are developed by each company?</li>
<li>How many emerging drugs are in mid-stage, and late-stage of development for the CAR-T Treatment?</li>
<li>What are the key collaborations (Industry&ndash;Industry, Industry&ndash;Academia), Mergers and acquisitions, licensing activities related to the CAR-T therapeutics?</li>
<li>What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?</li>
<li>What are the clinical studies going on for CAR-T and their status?</li>
<li>What are the key designations that have been granted to the CAR-T emerging drugs?</li>
</ul>
Stay Updated with our Newsletters and Infographics:-&nbsp;
<ul>
<li><a href="https://www.delveinsight.com/infographics/cart-cell-therapy-competitive-landscape">CAR T-Cell Therapy Infographics</a></li>
<li><a href="https://www.delveinsight.com/infographics/car-t-cell-therapy-for-non-hodgkins-lymphoma-market">CAR T for NHL Market Infographic</a></li>
<li><a href="https://www.delveinsight.com/infographics/car-t-cell-therapy-for-acute-lymphoblastic-leukemia-market">CAR T for ALL Market</a></li>
<li><a href="https://www.delveinsight.com/infographics/car-t-cell-therapy-for-multiple-myeloma-market">CAR T for Multiple myeloma Market</a></li>
<li><a href="https://www.delveinsight.com/whitepaper-newsletter/car-t-cell-therapy-future-landscape">CAR-T Newsletter</a></li>
<li><a href="https://www.delveinsight.com/blog/">Latest DelveInsight Blogs</a></li>
</ul>

Introduction
Executive Summary
CAR-T: Overview
<ul>
<li class="MsoNormal">Introduction</li>
<li class="MsoNormal">Indications</li>
<li class="MsoNormal">Complications</li>
<li class="MsoNormal">Clinical Significance</li>
</ul>
Pipeline Therapeutics
<ul>
<li class="MsoNormal">Comparative Analysis</li>
</ul>
Therapeutic Assessment
<ul>
<li class="MsoNormal">Assessment by Product Type</li>
<li class="MsoNormal">Assessment by Stage and Product Type</li>
<li class="MsoNormal">Assessment by Route of Administration</li>
<li class="MsoNormal">Assessment by Stage and Route of Administration</li>
<li class="MsoNormal">Assessment by Molecule Type</li>
<li class="MsoNormal">Assessment by Stage and Molecule Type</li>
</ul>
CAR-T&ndash; DelveInsight&rsquo;s Analytical Perspective
Late Stage Products (Phase III)
<ul>
<li>Comparative Analysis</li>
</ul>
Drug name: Company name
<ul>
<li class="MsoNormal">Product Description</li>
<li class="MsoNormal">Research and Development</li>
<li class="MsoNormal">Product Development Activities</li>
</ul>
Drug profiles in the detailed report&hellip;..
Mid Stage Products (Phase II)
<ul>
<li>Comparative Analysis</li>
</ul>
Descartes-08: Cartesian Therapeutics
<ul>
<li class="MsoNormal">Product Description</li>
<li class="MsoNormal">Research and Development</li>
<li class="MsoNormal">Product Development Activities</li>
</ul>
Drug profiles in the detailed report&hellip;..
Early Stage Products (Phase I) 
<ul>
<li>Comparative Analysis</li>
</ul>
ATA3219: Atara Biotherapeutics 
<ul>
<li class="MsoNormal">Product Description</li>
<li class="MsoNormal">Research and Development</li>
<li class="MsoNormal">Product Development Activities</li>
</ul>
Drug profiles in the detailed report&hellip;..
Preclinical and Discovery Stage Products 
<ul>
<li>Comparative Analysis</li>
</ul>
Drug name: Company name
<ul>
<li class="MsoNormal">Product Description</li>
<li class="MsoNormal">Research and Development</li>
<li class="MsoNormal">Product Development Activities</li>
</ul>
Drug profiles in the detailed report&hellip;..
Inactive Products
<ul>
<li>Comparative Analysis</li>
</ul>
CAR-T Key Companies
CAR-T Key Products
CAR-T- Unmet Needs
CAR-T- Market Drivers and Barriers
CAR-T- Future Perspectives and Conclusion
CAR-T Analyst Views
CAR-T Key Companies
 
Appendix

CAR-T Pipeline

CAR-T Pipeline Insight, 2025

CAR-T Pipeline Insights, 2025 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the  CAR-T market